Search results for "SCHEDULE"

showing 10 items of 567 documents

Patients Who Miss Initial Appointments in Community Psychiatry? a Spanish Community Analysis

1999

Objectives : To identify factors that predict which patients, when referred by their GP, make a first appointment at a Mental Health Centre and then fail to attend. Method: Sequential observational study in which data was collected for one year on all the people (1311) with an arranged date for an initial appointment at an urban Community Mental Health Centre. Results: Approximately 25% of patients who request an initial appointment fail to attend. The variables that predict non-attendance are: the lack of a telephone number for contact, the time lapse before the appointment, and when drug-addiction is the reason for requesting the appointment. One variable that results in a specific kind o…

AdultMale050103 clinical psychologymedicine.medical_specialtyeducation030209 endocrinology & metabolismAppointments and Schedules03 medical and health sciences0302 clinical medicineCommunity analysisTelephone numbermedicineHumans0501 psychology and cognitive sciencesCommunity PsychiatryPsychiatryhealth care economics and organizationsbusiness.industry05 social sciencesMental healthUrban communityCommunity Mental Health ServiceshumanitiesPsychiatry and Mental healthSpainPatient ComplianceFemaleObservational studybusinessInternational Journal of Social Psychiatry
researchProduct

Effect of single-dose and short-term administration of quercetin on the pharmacokinetics of talinolol in humans – Implications for the evaluation of …

2013

Quercetin has been shown to inhibit intestinal P-glycoprotein-mediated drug efflux. A crossover clinical study was performed in 10 healthy volunteers to assess the effect of single-dose and repeated quercetin intake on the pharmacokinetics of talinolol, a substrate of intestinal P-glycoprotein. Unexpectedly, mean area under the plasma concentration-time curve (AUC0-48h) and maximal plasma concentration (cmax) were slightly decreased following concomitant and short-term quercetin administration (3186.0 versus 2468.3 and 2527.7 ng h/ml, p>0.05; 309.7 versus 212.0 and 280.6 ng/ml, p>0.05). Individual analysis revealed that talinolol AUC0-48h was lowered by 23.9% up to 60.6% in 5 subjects and c…

AdultMaleATP Binding Cassette Transporter Subfamily BFlavonoidCmaxAdministration OralPharmaceutical SciencePharmacologyDrug Administration SchedulePropanolaminesYoung Adultchemistry.chemical_compoundPharmacokineticsHumansDrug Interactionsheterocyclic compoundsIntestinal MucosaP-glycoproteinchemistry.chemical_classificationCross-Over StudiesDose-Response Relationship DrugbiologyBiological TransportTransporterMiddle AgedHealthy VolunteersIntestineschemistrybiology.proteinFemaleQuercetinEffluxQuercetinTalinololEuropean Journal of Pharmaceutical Sciences
researchProduct

Addition of Low-Dose Fluvoxamine to Low-Dose Clozapine Monotherapy in Schizophrenia: Drug Monitoring and Tolerability Data from a Prospective Clinica…

1999

Combining fluvoxamine and clozapine may be a strategy to improve therapeutic effects on negative symptoms in schizophrenic patients. Fluvoxamine, however, markedly inhibits the metabolism of clozapine, and hazardous side effects may result. This study prospectively investigated the safety and tolerability of an add-on therapy with fluvoxamine to a clozapine monotherapy in schizophrenic patients. Sixteen schizophrenic patients received 50 mg fluvoxamine as a comedication after having reached steady-state conditions under clozapine monotherapy. Patients were monitored for subjective adverse events, laboratory parameters, EEG and ECG recordings, orthostatic hypotension and their psychopatholog…

AdultMaleAdolescentMatched-Pair AnalysisFluvoxamineDrug Administration ScheduleOrthostatic vital signsmedicineHumansDrug InteractionsPharmacology (medical)Prospective StudiesAdverse effectClozapineClozapineTherapeutic effectGeneral MedicineMiddle AgedDrug interactionPsychiatry and Mental healthTreatment OutcomeTolerabilityFluvoxamineAnesthesiaSchizophreniaAntidepressive Agents Second-GenerationDrug Therapy CombinationFemaleDrug MonitoringPsychologyReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugPharmacopsychiatry
researchProduct

An assessment of prime‐boost vaccination schedules with AS03A‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults

2012

Please cite this paper as: Gillard et al. (2012) An assessment of prime‐boost vaccination schedules with AS03A‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750‐2659.2012.00349.x. Background  Long‐term persistence of immune response and safety of an H5N1 prepandemic influenza vaccine adjuvanted with AS03 (an α‐tocopherol oil‐in‐water emulsion‐based adjuvant system) was evaluated using various prime‐boost schedules that mimicked potential pandemic scenarios (NCT00430521). Methods  Five hundred and twelve healthy adults aged 18–60 years received primary vaccination with one or two doses (0, 21 days schedule…

AdultMaleAdolescentalpha-TocopherolImmunization SecondaryAntibodies ViralAS03Young Adultprime‐boostAdjuvants ImmunologicInfluenza HumanHumansAdjuvantImmunization ScheduleInfluenza A Virus H5N1 SubtypeVaccinationOriginal ArticlesH5N1Hemagglutination Inhibition TestsMiddle AgedAntibodies NeutralizingTreatment OutcomeInfluenza VaccinesOriginal ArticleFemaleinfluenzaprepandemicInfluenza and Other Respiratory Viruses
researchProduct

Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC …

1998

Despite the wide use of G-CSF for mobilization of PBPC the best dose and schedule of G-CSF has not been definitively established. In this study we have compared three different schedules of G-CSF for mobilization of PBPC in normal donors including a single daily dose of 10 microg/kg/day for 5 days (21 donors) and doses of 6 (21 donors) or 8 microg/kg/12 h (6 donors) for 5 days. We demonstrate that G-CSF at doses of 6 and 8 microg/kg/12 h mobilizes significantly more CD34+ cells/ml of blood (83.3 +/- 6.7 and 121 +/- 6.9, respectively) than 10 microg/kg/day (71.6 +/- 6.5). Mobilization with 6 or 8 microg/kg/12 h of G-CSF was also associated with collection of significantly more CD34+ cells in…

AdultMaleAdolescentmedicine.medical_treatmentBlood volumeHematopoietic stem cell transplantationDrug Administration ScheduleAndrologyGranulocyte Colony-Stimulating FactorHumansTransplantation HomologousMedicinePlateletProgenitor cellChildAgedTransplantationMobilizationbusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedHematopoietic Stem Cell MobilizationBlood Cell CountGranulocyte colony-stimulating factorTransplantationmedicine.anatomical_structureImmunologyBlood Component RemovalFemaleBone marrowbusinessBone Marrow Transplantation
researchProduct

Comparison between Spanish young and elderly people evaluated using Rivermead Behavioural Memory Test

2010

The first objective of this work was to compare scores obtained in the daily memory function between young and elderly people, and to check whether there are differences between the groups for each of the profile scores obtained in the memory test. A second aim of this paper is to study the relationship between everyday memory and age, while controlling for gender and educational level. The total and profile scores obtained in the Rivermead Behavioural Memory Test were compared in a sample of 60 young and 120 elderly people from Valencia (Spain). Results showed significant differences between the two groups: those between 18 and 30 years obtained a higher average than those over 65. Once th…

AdultMaleAgingAdolescentPsychometricsJovesExperimental and Cognitive PsychologyNeuropsychological TestsDevelopmental psychologyYoung AdultSex FactorsMemorySurveys and QuestionnairesmedicineHumansYoung adultAgedAged 80 and overAnalysis of Variancemedicine.diagnostic_testMemoriaRivermead Behavioural Memory TestCognitionNeuropsychological testPsychiatry and Mental healthNeuropsychology and Physiological PsychologySpainAgeingEducational StatusMain effectFemaleTrastorns de la memòria en la vellesaGeriatrics and GerontologyMental Status SchedulePsychologyClinical psychology
researchProduct

Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.

2014

Abstract Introduction Epistaxis is the most frequent manifestation in hereditary hemorrhagic telangiectasia, in which no optimal treatment exists. It can lead to severe anemia and reduced quality of life. Positive effects of tranexamic acid, an antifibrinolytic drug, have been reported on epistaxis related to this disorder. We sought to evaluate the efficacy of treating nosebleeds in hereditary hemorrhagic telangiectasia with tranexamic acid. Materials and Methods In a randomized, double-blind, placebo controlled, cross-over phase IIIB study, 1 gram of tranexamic acid or placebo was given orally 3 times daily for 3 months for a total of 6 months. Results 22 patients were included in the int…

AdultMaleAntifibrinolyticTime Factorsmedicine.drug_classMedizinAdministration OralPlaceboDrug Administration ScheduleDouble blindQuality of lifeDouble-Blind MethodGermanymedicineHumansTelangiectasiaAgedDiminutionCross-Over Studiesbusiness.industryHematologyMiddle AgedAntifibrinolytic AgentsClinical trialEpistaxisTreatment OutcomeTranexamic AcidAnesthesiaFemaleTelangiectasia Hereditary Hemorrhagicmedicine.symptombusinessTranexamic acidmedicine.drugThrombosis research
researchProduct

CEA and CA19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-ho…

2001

Summary Background There have been contradictory reports on the benefit of CEA and CA 19-9 measurements in patients with metastatic colorectal cancer using palliative chemotherapy. The object of this study was to examine the diagnostic accuracy of monitoring of palliative chemotherapy by means of CEA and CA19-9. Patients and methods The tumour markers CEA and CA 19-9 were subjected to serial measurement in patients with metastatic colorectal cancer (n = 90) using palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-FU with FA and were compared with objective response according to WHO criteria. 85 patients could be evaluated. 43 patients (51%) initially had elevated…

AdultMaleAntimetabolites Antineoplasticmedicine.medical_specialtyPalliative careCA-19-9 AntigenColorectal cancerLeucovorinSensitivity and SpecificityGastroenterologyDrug Administration ScheduleFolinic acidCarcinoembryonic antigenRecurrenceInternal medicinemedicineHumansInfusions IntravenousAgedTumor markerbiologybusiness.industryPalliative CareHematologyMiddle Agedmedicine.diseaseChemotherapy regimenCarcinoembryonic AntigenSurgeryOncologyFluorouracilbiology.proteinFemaleCA19-9FluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

A Bayesian Method for Predicting 5‐Fluorouracil Pharmacokinetic Parameters Following Short‐Term Infusion in Patients With Colorectal Cancer

2003

Abstract The objective of this study was to develop a population pharmacokinetic model and validate it using a Bayesian approach for predicting, a priori and a posteriori , the individual volume of distribution ( V d ) and clearance ( Cl ) of 5‐fluorouracil (5‐FU) given as short‐term intravenous infusion in weekly and multiple doses. Forty‐four patients were divided in group A (5‐FU weekly doses) including 27 patients with nonmetastatic colorectal adenocarcinoma treated with 450 mg/m 2 of 5‐FU, 1 day per week for 48 doses, plus oral levamisol (50 mg/8 h) for 3 days, every 15 days and group B (5‐FU multiple doses) including 17 patients with metastatic colorectal adenocarcinoma, receiving 5‐F…

AdultMaleAntimetabolites Antineoplasticmedicine.medical_specialtyPopulationUrologyPharmaceutical ScienceRenal functionModels BiologicalDrug Administration ScheduleFolinic acidPharmacokineticsInternal medicineBlood plasmamedicineHumansInfusions IntravenouseducationAgedBody surface areaVolume of distributioneducation.field_of_studybusiness.industryBayes TheoremMiddle AgedNONMEMEndocrinologyArea Under CurveFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugJournal of Pharmaceutical Sciences
researchProduct

The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing

2004

Budesonide/formoterol in a single inhaler is an effective therapy for asthma. We investigated whether adjustable maintenance dosing with budesonide/formoterol could maintain health-related quality of life (HRQL) and asthma control.Asthma patients (n = 4025) received budesonide/formoterol (Symbicort 160/4.5 microg) 2 inhalations twice daily (b.i.d.) for 4 weeks during run-in of this open, multicentre study. Patients were randomised to adjustable dosing (budesonide/formoterol 1 inhalation b.i.d.; stepping up to 2 or 4 inhalations bid for 1 week if asthma worsened) or fixed dosing (budesonide/formoterol 2 inhalations b.i.d.), for 12 weeks. Change in HRQL (standardised Asthma Quality of Life Qu…

AdultMaleBudesonideAdolescentDrug Administration Scheduleimmune system diseasesFormoterol FumarateAdministration InhalationmedicineHumansAnti-Asthmatic AgentsMetered Dose InhalersDosingBudesonideAgedAsthmaInhalationbusiness.industryInhalerGeneral MedicineMiddle Agedmedicine.diseaseAsthmaRespiratory Function Testsrespiratory tract diseasesDrug CombinationsTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaQuality of LifeFemaleFormoterol FumarateFormoterolbusinessmedicine.drugCurrent Medical Research and Opinion
researchProduct